Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

ME Staff 8-k
-
0

Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01. Other Events

On September26, 2017 and September 27, 2017, Herriot Tabuteau, M.D., Axsome Therapeutics’ (the “Company”) Chief Executive Officer will present at the Ladenburg Thalmann 2017 Healthcare Conference and The Cantor Fitzgerald Global Healthcare Conference (the “Conferences”), respectively. Dr.Tabuteau will be presenting at the Conferences to provide an overview of the Company’s business and late-stage clinical product candidates, AXS-02, AXS-05, and AXS-06.

Attached as Exhibit99.1 to this Current Report on Form8-K is a copy of the updated presentation slide deck to be used in connection with these planned presentations.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Corporate Presentation


Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a17-22140_1ex99d1.htm EX-99.1 Exhibit 99.1    NASDAQ: AXSM September 2017 © 2017,…
To view the full exhibit click here

About Axsome Therapeutics,Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).